Obesity in Children
Methodology & AI Transparency ⓘ
Obesity in Children Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Obesity means having too much body fat.
- 2 Real-world patient consensus: Mapped to Weight Management & Metabolic Syndrome under ICD-10-CM E65.2 for Obesity in Children clinical workups.
- 3 Typical cash cost range: Workup highlights for Obesity in Children (E65.2): hepatic steatosis screening in Obesity in Children (E65.2: (FIB-4)).
- 4 Top reported side effects / signs: Longitudinal Obesity in Children monitoring tracks ALT & Fasting in Obesity in Children (E65.2: Triglycerides) toward ALT < 25 U/L; TG < 100 mg/dL (E65.2).
Ask our AI Specialists anything about Obesity in Children
What Is Obesity in Children?
Obesity means having too much body fat. It is different from being overweight, which means weighing too much. Both terms mean that a person's weight is greater than what's considered healthy for his or her height. Children grow at different rates, so it isn't always easy to know when a child has obesity or is overweight. Ask your health care provider to check whether your child's weight and height are in a healthy range. If a weight-loss program is necessary, involve the whole family in healthy habits so your child doesn't feel singled out.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Obesity in Children (E65.2) center on hypothalamic arcuate nucleus in Obesity in Children (E65.2: leptin resistance). Cross-referenced with NIH MeSH (Pediatric Obesity, Obesity), targeted weight & metabolism interventions aim to normalize ALT & Fasting in Obesity in Children (E65.2: Triglycerides).
Common Symptoms & Clinical Signs
- • Serving more fruits and vegetables
- • Buying fewer soft drinks and high-fat, high-calorie snack foods
- • Presentation of Obesity in Children (E65.2): persistent hunger signaling [Obesity in Children E65.2]
- • Secondary Obesity in Children clinical sign: co-existing blood pressure, in Obesity in Children (E65.2: triglyceride, or fasting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Obesity in Children Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E65.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ALT & Fasting in Obesity in Children (E65.2: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E65.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Obesity in Children (E65.2: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E65.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Obesity in Children E65.2] | < 0.50 (E65.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Obesity in Children
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Benzphetamine Hydrochloride Benzphetamine Hydrochloride Generic • RxCUI 904368 | Sympathomimetic Amine Anorectic | 81% | $3.0500 | $ 132.03 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Obesity in Children)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
| New Insights on Tirzepatide as a novel effective and safe strategy for treating: What a 11,758-Participant Study Found Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Frontiers in public health • 2024-01-15 • Meta-Analysis | N = 11,758 | 99/100 | PMID 38356942 ↗ |
| New Insights on Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the: What a 12,300-Participant Study Found GLP-1RAs triggered more gastrointestinal side effects than placebo, with no in-between difference. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2023-03-15 • Meta-Analysis | N = 12,300 | 99/100 | PMID 36579723 ↗ |
| New Insights on Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the: What a 1,145-Participant Study Found In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. JACC. Heart failure • 2025-11-15 • Randomized Controlled Trial | N = 1,145 | 96/100 | PMID 41045908 ↗ |
| New Insights on Coadministered Cagrilintide and Semaglutide in Adults with Overweight or: What a 3,417-Participant Study Found Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 3,417 | 96/100 | PMID 40544433 ↗ |
Obesity in Children Patient Community & “People Like Me” Threads
Filter Obesity in Children community threads and patient logs by age, biological sex, dosage, and treatment duration.